Psychosis, agitation, and antipsychotic treatment in dementia

American Journal of Psychiatry

Volumn 170, Issue 9, 2013, Pages 957-960

  Devanand, D P ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

AGITATION; BEHAVIOR DISORDER; DEMENTIA; DISEASE ASSOCIATION; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HEART DISEASE; HUMAN; MENTAL PERFORMANCE; MORTALITY; NURSING HOME; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; TIME OF DEATH; UNSPECIFIED SIDE EFFECT;

EID: 84883684375     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.13060767     Document Type: Review

References (16)

1. Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH: Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010; 170:89-95
2. Scarmeas N, Brandt J, Blacker D, Albert M, Hadjigeorgiou G, Dubois B, Devanand D, Honig L, Stern Y: Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol 2007; 64:1755-1761
3. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934-1943
4. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG: Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306:1359-1369
5. Lopez OL, Becker JT, Chang Y-F, Sweet RA, Aizenstein H, Snitz B, Saxton J, McDade E, Kamboh MI, DeKosky ST, Reynolds CF III, Klunk WE: The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry 2013; 170:1051-1058
6. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkälä KH: Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a 2-year prospective study. Am J Geriatr Psychiatry 2007; 15:416-424
7. Simoni-Wastila L, Ryder PT, Qian J, Zuckerman IH, Shaffer T, Zhao L: Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 2009; 17:417-427
8. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S: Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population-based cohort study. BMJ 2012; 344:e977
9. Devanand DP, Marder K, Michaels KS, Sackeim HA, Bell K, Sullivan MA, Cooper TB, Pelton GH, Mayeux R: A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998; 155:1512-1520
10. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H: The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of four placebocontrolled clinical trials. Int J Geriatr Psychiatry 2007; 22:475-484
11. Centers for Medicare and Medicaid Services: Initiative to improve behavioral health and reduce the use of antipsychotic medications in nursing homes residents' video streaming event. www.cms.gov/Medicare/ Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/ Spotlight.html
12. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A; the HGEU Study Group: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000; 57:968-976
13. Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B: Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012; 367:1497-1507
14. Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L; Alzheimer's Disease Cooperative Study; Valproate Nursing Home Study Group: Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 2005; 13:942-949
15. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210
16. Brodaty H, Arasaratnam C: Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012; 169:946-953